Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone ...
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced a significant milestone for its proprietary Nectin-4 targeted ADC (9MW2821). On January 8, 2025, ...
Denali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, ...
The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with ...
A breakthrough in prostate cancer treatment has seen a drug shrink tumours in men with advanced disease ...
Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...
Johnson & Johnson (NYSE:JNJ) has received Priority Review designation from the FDA for the Biologics License Application for ...
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...
This week, odd new details emerge as authorities continue to investigate the New Year's Day Tesla Cybertruck explosion in Las ...
A new study demonstrates that a first-of-its-kind platform using artificial intelligence (AI) could help clinicians and patients assess whether and how much an individual patient may benefit from a ...